期刊文献+

前列腺癌调强放疗和三维适形放疗剂量学对比研究 被引量:4

A comparison between intensity modulated radiotherapy and three-dimensional conformal radiotherapy in dose distribution in prostate cancer
下载PDF
导出
摘要 目的:通过对前列腺癌调强和适形放疗方案的比较,选择前列腺癌最佳放疗方案。方法:选取8例前列腺癌患者,经过增强CT模拟定位后参考盆腔磁共振结果勾画大体肿瘤体积,按统一标准外扩临床靶体积和PTV,应用三维治疗计划系统为每例患者设计调强适形放疗计划(IMRT)和三维适形放疗计划,在规定PTV至少达到95%处方剂量前提下根据剂量体积直方图比较两种计划靶区剂量分布及直肠、膀胱、股骨头等正常组织受量的差异。结果:调强放疗的靶区适形度指数、均匀性指数、处方剂量覆盖PTV百分比较好,减少了直肠、膀胱和股骨头剂量,差异均有统计学意义(P<0.05)。结论:前列腺癌采用IMRT是目前最佳的一种放疗方法。 Objective To find the optimal radiotherapy for prostate cancer through comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy (3D-CRT) technique. Methods Eight patients with prostate cancer underwent CT simulation. GTV was contour on the CT image, referring the MRI, then CTV and plan target volume (PTV) were also defined using the same criteria. Intensity modulated radiotherapy and 3D-CRT were designed at the sameTPS. The difference of exposure doses between target area and critical organ was compared by dose volumehistogram with the PTV must reach 95% of the prescription dose. Results Compared with 3D-CRT, the target dose was well-distributed, and the absorbed dose and volume in rectum, bladder and femoral head were obviously reduced. Conclusion Intensity modulated radiotherapy is the optimal radiotherapy for prostate cancer.
出处 《东南大学学报(医学版)》 CAS 2009年第2期132-135,共4页 Journal of Southeast University(Medical Science Edition)
关键词 前列腺癌 调强适形放疗 三维适形放疗 prostate cancer intensity modulated radiotherapy three-dimensional conformal radiotherapy
  • 相关文献

参考文献10

  • 1HANKS G E,HANLON A L,EPSTEIN B,et al.Dose response in prostate cancer with 8-12 years’follow-up[J].Int J Radiat Oncol Biol Phys,2002,54:427-435.
  • 2BRAGG C M,CONWAY J,ROBINSON M H.The roleofintensi-ty-modulated radiothera-Py in the treatment of parotid tumors[J].Int J Radiat Oncol Biol Plays,2002,52(3):729-738.
  • 3LIU H,WANG X,DONG L,et al.Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small cell lung cancer[J].Int J Radiat Oncol Biol Phys,2004,58(4):1268-1279.
  • 4CHAUVET B,OOZEER R,BEY P,et al.Radioth rapie conformationnelle des cancer de la prostate:revue générale[J].Cancer Radiother,1999,3:393-406.
  • 5DEARNALEY D,HALL E,JACKSON C,et al.PhaseⅢ trial of conformal radiothepy following neoadjuvant hormone treatement in early prostate cancer[J].Proc ASTRO,2002,54:228-232.
  • 6房辉,李晔雄.前列腺癌的适形和调强适形放疗[J].癌症进展,2005,3(5):449-460. 被引量:10
  • 7金大伟,戴建荣,李晔雄,余子豪.前列腺癌调强放疗的治疗方案比较[J].中华放射肿瘤学杂志,2005,14(1):47-51. 被引量:43
  • 8ASBELL S O,MARTZ K L,SHIN K H,et al.Impact of surgical stage in evaluating the radiotherapeutic outcome in RTOG 77-06,a phaseⅢstudy for T1BN0M0(A2)And T2N0M0(B) prostate cancer[J].Int J Radiat Oncol Biol Phys,1998,40:769-773.
  • 9KUBAN D,POLLACK A,HUANG E,et al.Hazards of escalation in prostate cancer radiotherapy[J].Int J Radiat Oncol Biol Phys,2003,57:1260-1266.
  • 10FISCH B M,PICKETT B,WEINBERG V,et al.Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer[J].Adult Urology,2001,57:955-961.

二级参考文献47

  • 1[1]Jewett HJ. The present status of radical prostatectomy for stages A and B prostate cancer. Urol Clin North Am, 1975, 2:105
  • 2[2]Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and psistent/recurrent detectable PSA after radical prostatectomy. Urology, 1994, 44:371
  • 3[3]Kestin LY, Goldstein NS, Vicini FA, et al. Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys, 2002, 54:686
  • 4[4]Bagshaw M. Radiotherapeutic treatment of prostate cancer with pelvic node Involvement. Urol Clin North Am, 1984, 11:297
  • 5[5]Asbell SO, Martz KL, Shin KH, et al. Impact of surgical stage in evaluating the radiotherapeutic outcome in RTOG 77-06,aphase Ⅲ study forT1BN0Mo (A2) AndT2N0M0 (B) prostate cancer. Int J Radiat Oncol Biol Phys, 1998, 40:769
  • 6[6]Roach Ⅲ M, DeSilvio M, Lawton C, et al. Phase Ⅲ trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression:Radiation therapy oncology group 9413. J Clin, Oncol, 2003,21:1904
  • 7[7]Haken RKT, Forman JD, Heimburger DK, et al. Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys, 20:1991, 1317
  • 8[8]Langen KM., Jones TL, et al. Organ motion and its management. Int J Radiat Oncol Biol Phys, 2001, 50:265
  • 9[9]Mah D, Freedman G, Milestone B, et al. Measurement of prostate motion using magnetic resonance imaging. Int J Radiat Oncol Biol Phys, 2002, 54:568
  • 10[10]Trichter FDSc, Ennis RD, et al. Prostate localization using transabdominal ultrasound imaging. Int J Radiat Oncol Biol Phys, 2003, 56:1225

共引文献51

同被引文献49

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部